Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
172 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-24 |
Cash Flow (TTM) (Millions $) |
-30 |
Capital Exp. (TTM) (Millions $) |
0 |
Tyme Technologies Inc.
Tyme Technologies Inc. is a pharmaceutical company focused on the research and development of innovative cancer treatments. It utilizes its proprietary technology platform, known as SM-88, to develop therapies that target the underlying metabolic processes of cancer cells. SM-88 is an oral monotherapy designed to disrupt the cancer cell's ability to produce energy, ultimately leading to cell death. The company aims to address various forms of cancer, including pancreatic, prostate, and breast cancer, among others. Tyme Technologies Inc. is headquartered in New York City, United States, and is committed to improving the lives of cancer patients through its novel treatment options.
Company Address: 1 Pluckemin Way â?? Suite 103 Bedminster 7921 NJ
Company Phone Number: 461-2315 Stock Exchange / Ticker: NASDAQ TYME
|